FDA Accepts Drug Quality Of Life Claims From Secondary Endpoints - Bristol
Executive Summary
FDA sometimes allows quality of life claims for drugs based on secondary endpoints in clinical trials, Bristol-Myers Squibb Health Economics Policy & External Relations Group Director Joseph Jackson, PhD, told a Drug Information Association meeting March 12 in Washington, D.C.
You may also be interested in...
FDA Quality Of Life, Pharmacoeconomic Guidance Development On Hold
FDA development of guidances for including quality of life claims in drug labeling and promotions and for formulary-directed pharmacoeconomic information is on hold until more information is collected.
Celebrex TV Ads Modified After FDA Says Pharmacia Overstated Efficacy
Pharmacia modified a Celebrex direct-to-consumer advertising campaign after FDA found that television spots for the product exaggerated the efficacy of the arthritis drug.
Bristol/Gillette Vaniqa To Be Launched In September For Facial Hair Removal
Bristol-Myers Squibb is collecting quality of life data to document the psychosocial benefits of the prescription facial hair removal cream Vaniqa.